drugset
drugset / Trial / NCT00508430

ASP 8825 - Study in Patients With Painful Diabetic Polyneuropathy

NCT00508430 ↗

Phase 2 Terminated 199 enrolled Astellas Pharma Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To demonstrate the superiority of ASP8825 over placebo and dose response in patients with painful diabetic polyneuropathy.

Timeline

Start
2007-07
Primary completion
2008-11
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject gabapentin enacarbil Small molecule — Oral

Indications

diabetic polyneuropathy